Multiple sclerosis (MS) is characterised by a diffuse inflammatory response mediated by microglia and astrocytes. Brain translocator protein (TSPO) positron-emission tomography (PET) and [myo-inositol] magnetic resonance spectroscopy (MRS) were used together to assess this.
Objective:
To explore the in vivo relationships between MRS and PET [11C]PBR28 in MS over a range of brain inflammatory burden.
Methods:
A total of 23 patients were studied. TSPO PET imaging with [11C]PBR28, single voxel MRS and conventional magnetic resonance imaging (MRI) sequences were undertaken. Disability was assessed by Expanded Disability Status Scale (EDSS) and Multiple Sclerosis Functional Composite (MSFC).
Results:
[11C]PBR28 uptake and [myo-inositol] were not associated. When the whole cohort was stratified by higher [11C]PBR28 inflammatory burden, [myo-inositol] was positively correlated to [11C]PBR28 uptake (Spearman’s ρ = 0.685, p = 0.014). Moderate correlations were found between [11C]PBR28 uptake and both MRS creatine normalised N-acetyl aspartate (NAA) concentration and grey matter volume. MSFC was correlated with grey matter volume (ρ = 0.535, p = 0.009). There were no associations between other imaging or clinical measures.
Conclusion:
MRS [myo-inositol] and PET [11C]PBR28 measure independent inflammatory processes which may be more commonly found together with more severe inflammatory disease. Microglial activation measured by [11C]PBR28 uptake was associated with loss of neuronal integrity and grey matter atrophy.
GiannettiPPolitisMSuPet al. Microglia activation in multiple sclerosis black holes predicts outcome in progressive patients: An in vivo [(11)C](R)-PK11195-PET pilot study. Neurobiol Dis2014; 65: 203–210.
2.
VersijptJDebruyneJCVan LaereKJet al. Microglial imaging with positron emission tomography and atrophy measurements with magnetic resonance imaging in multiple sclerosis: A correlative study. Mult Scler2005; 11: 127–134.
3.
KapellerPMcLeanMAGriffinCMet al. Preliminary evidence for neuronal damage in cortical grey matter and normal appearing white matter in short duration relapsing-remitting multiple sclerosis: A quantitative MR spectroscopic imaging study. J Neurol2001; 248: 131–138.
4.
BitschABruhnHVougioukasVet al. Inflammatory CNS demyelination: Histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol1999; 20: 1619–1627.
5.
RaeCD.A guide to the metabolic pathways and function of metabolites observed in human brain 1H magnetic resonance spectra. Neurochem Res2014; 39: 1–36.
6.
FuLMatthewsPMDe StefanoNet al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain1998; 121(Pt 1): 103–113.
7.
MatthewsPMDattaG.Positron-emission tomography molecular imaging of glia and myelin in drug discovery for multiple sclerosis. Expert Opin Drug Discov2015; 10: 557–570.
8.
BanatiRBNewcombeJGunnRNet al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: Quantitative in vivo imaging of microglia as a measure of disease activity. Brain2000; 123(Pt 11): 2321–2337.
9.
ColasantiAGuoQMuhlertNet al. In vivo assessment of brain white matter inflammation in multiple sclerosis with (18)F-PBR111 PET. J Nucl Med2014; 55: 1112–1118.
10.
RissanenETuiskuJRokkaJet al. In vivo detection of diffuse inflammation in secondary progressive multiple sclerosis using PET imaging and the radioligand 11C-PK11195. J Nucl Med2014; 55: 939–944.
11.
GuoQOwenDRRabinerEAet al. Identifying improved TSPO PET imaging probes through biomathematics: The impact of multiple TSPO binding sites in vivo. Neuroimage2012; 60: 902–910.
12.
Cosenza-NashatMZhaoMLSuhHSet al. Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain. Neuropathol Appl Neurobiol2009; 35: 306–328.
13.
PolmanCHReingoldSCBanwellBet al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol2011; 69: 292–302.
14.
OwenDRYeoAJGunnRNet al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab2012; 32: 1–5.
15.
BagoryMDurand-DubiefFIbarrolaDet al. Implementation of an absolute brain 1H-MRS quantification method to assess different tissue alterations in multiple sclerosis. IEEE Trans Biomed Eng2012; 59: 2687–2694.
16.
OggRJKingsleyPBTaylorJSet al. WET, a T1- and B1-insensitive water-suppression method for in vivo localized 1H NMR spectroscopy. J Magn Reson B1994; 104: 1–10.
17.
ProvencherSW.Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med1993; 30: 672–679.
18.
SarchielliPPresciuttiOPelliccioliGPet al. Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients. Brain1999; 122(Pt 3): 513–521.
19.
SmithSMZhangYJenkinsonMet al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage2002; 17: 479–489.
20.
LoganJFowlerJSVolkowNDet al. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab1996; 16: 834–840.
21.
CollsteKForsbergAVarroneAet al. Test-retest reproducibility of [(11)C]PBR28 binding to TSPO in healthy control subjects. Eur J Nucl Med Mol Imaging2016; 43: 173–183.
22.
SalinasCASearleGEGunnRN.The simplified reference tissue model: Model assumption violations and their impact on binding potential. J Cereb Blood Flow Metab2015; 35: 304–311.
23.
GuoQOwenDRRabinerEAet al. A graphical method to compare the in vivo binding potential of PET radioligands in the absence of a reference region: Application to [11C]PBR28 and [18F]PBR111 for TSPO imaging. J Cereb Blood Flow Metab2014; 34: 1162–1168.
24.
GarveyLJPaveseNRamlackhansinghAet al. Acute HCV/HIV coinfection is associated with cognitive dysfunction and cerebral metabolite disturbance, but not increased microglial cell activation. PLoS ONE2012; 7: e38980.
25.
PopescuBFPirkoILucchinettiCF.Pathology of multiple sclerosis: Where do we stand?Continuum2013; 19: 901–921.
26.
BrexPAParkerGJLearySMet al. Lesion heterogeneity in multiple sclerosis: A study of the relations between appearances on T1 weighted images, T1 relaxation times, and metabolite concentrations. J Neurol Neurosurg Psychiatry2000; 68: 627–632.
27.
MurrayMEPrzybelskiSALesnickTGet al. Early Alzheimer’s disease neuropathology detected by proton MR spectroscopy. J Neurosci2014; 34: 16247–16255.
28.
MagliozziRHowellOWReevesCet al. A gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol2010; 68: 477–493.
29.
VercellinoMMaseraSLorenzattiMet al. Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. J Neuropathol Exp Neurol2009; 68: 489–502.
30.
LlufriuSKornakJRatineyHet al. Magnetic resonance spectroscopy markers of disease progression in multiple sclerosis. JAMA Neurol2014; 71: 840–847.
31.
De StefanoNFilippiMMillerDet al. Guidelines for using proton MR spectroscopy in multicenter clinical MS studies. Neurology2007; 69: 1942–1952.
32.
AudoinBIbarrolaDMalikovaIet al. Onset and underpinnings of white matter atrophy at the very early stage of multiple sclerosis – A two-year longitudinal MRI/MRSI study of corpus callosum. Mult Scler2007; 13: 41–51.
33.
GiannettiPPolitisMSuPet al. Increased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome. Brain2015; 138: 110–119.
34.
PolitisMGiannettiPSuPet al. Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. Neurology2012; 79: 523–530.
35.
ParkerCANabulsiNHoldenDet al. Evaluation of 11C-BU99008, a PET ligand for the imidazoline2 binding sites in rhesus brain. J Nucl Med2014; 55: 838–844.
